|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||MM485|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: MM485 (ECACC 11072803)|
|Keywords:||Human melanoma metastatic site lymph node|
|Cell Line Description:||MM485 is a human melanoma derived from a metastatic site (lymph node). Cell Bank Australia reference number CBA-1355|
|Tissue of Origin:||Skin|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Optimal split ratio 1:4 (seeding density 1.2 x104 cells/cm2).Cells incubated at 37°C with 5% CO2.Harvest the cells using 0.05% Trypsin/EDTA at 37°C for 5 min.|
|Culture Medium:||RPMI 1640 (with 2mM L-Glutamine + 25mM HEPES) + 10% FBS|
|Depositor:||Peter Parsons - Queensland Institute of Medical Research, Australia|
|References:||Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK. 1997 CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 57(21):4868-75 PMID: 9354451.|
|Additional Bibliography:||Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringnér M, Hayward NK. 2004 Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. 23(23):4060-7 PMID: 15048078. Packer L, Pavey S, Parker A, Stark M, Johansson P, Clarke B, Pollock P, Ringner M, Hayward N. 2006 Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis. 27:1778-86. PMID: 16571650. Stark M, Hayward N. 2007 Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67(6):2632-42 PMID: 17363583.|
|Patents:||None specified by Depositor|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.